Zai Lab Limited (Zai Lab) disclosed in its Monthly Return for the period ended 31 March 2026 that it issued 6.00 million new ordinary shares during the month, lifting total issued share capital (excluding treasury shares) to 1.13 billion shares. No treasury shares were held or cancelled.

The company’s authorised share capital stayed unchanged at 5.00 billion ordinary shares with a par value of USD 0.000006 each, equivalent to USD 30,000.

New shares were allotted on 27 March 2026 to a trustee at a deemed consideration of HKD 0.00. The shares will satisfy vesting of restricted share units (RSUs), performance share units (PSUs) and potential option exercises granted under the 2015, 2017, 2022 and 2024 Equity Incentive Plans.

Option activity was robust: • 4.62 million options under the 2015 plan and 17,730 options under the 2022 plan were exercised, while 0.25 million (2015) and 2,000 (2022) options lapsed. • The 2024 plan added 7.36 million newly granted options, taking its outstanding option pool to 14.65 million shares. • Total cash proceeds from option exercises reached USD 0.38 million.

Equity-based awards also saw movement: 1.66 million RSUs and 1.82 million PSUs were granted under the 2024 plan, while a combined 0.30 million RSUs vested across the 2017, 2022 and 2024 schemes. Post-transaction, unvested awards cover approximately 25.60 million shares across the three active plans.

Zai Lab affirmed that it met the Hong Kong Main Board’s minimum 25% public-float requirement as of 31 March 2026, with 329.28 million ordinary shares held in the form of American Depositary Shares (ADS). No warrants, convertibles or treasury-share transactions were recorded during the month.